US Patent Issued to SHANGHAI VITALGEN BIOPHARMA on April 21 for "Recombinant AAV vectors for treating neurodegenerative disorders" (Chinese Inventors)

ALEXANDRIA, Va., April 21 -- United States Patent no. 12,605,467, issued on April 21, was assigned to SHANGHAI VITALGEN BIOPHARMA Co. LTD. (Shanghai).

"Recombinant AAV vectors for treating neurodegenerative disorders" was invented by Yezheng Tao (Shanghai), Shin-Shay Tian (Shanghai) and Xiaoping Zhao (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided is a recombinant adeno-associated viral (rAAV) vector comprising one or two of (a) to (c): (a) a nucleotide sequence encoding aromatic L-amino acid decarboxylase (AADC), (b) a nucleotide sequence encoding glucocerebrosidase (GBA1); and (c) a nucleotide sequence encoding a neurotrophic factor (NTF), such as cerebral dopamine neurotrophic factor (CD...